세계의 단핵구 활성화 시험(MAT) 시장

Global Monocyte Activation Tests (MAT) Market to Reach US$285.5 Million by 2030

The global market for Monocyte Activation Tests (MAT) estimated at US$94.7 Million in the year 2024, is expected to reach US$285.5 Million by 2030, growing at a CAGR of 20.2% over the analysis period 2024-2030. MAT Kits, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$157.2 Million by the end of the analysis period. Growth in the MAT Reagents segment is estimated at 22.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.2 Million While China is Forecast to Grow at 19.0% CAGR

The Monocyte Activation Tests (MAT) market in the U.S. is estimated at US$25.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$43.4 Million by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.3% and 17.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global Monocyte Activation Tests Market - Key Trends & Drivers Summarized

What Are Monocyte Activation Tests (MAT), and Why Are They So Crucial in Modern Biopharmaceutical Safety?

Monocyte Activation Tests (MAT) are in-vitro assays that detect the presence of pyrogens—fever-inducing substances, in pharmaceutical products, medical devices, and biologicals. These tests utilize human monocytes or monocytic cell lines, which, upon exposure to pyrogens, release pro-inflammatory cytokines like IL-6 and TNF-α. MAT offers a reliable alternative to traditional rabbit pyrogen tests (RPT) and Limulus Amebocyte Lysate (LAL) tests, making it a critical tool in ensuring the safety and quality of injectable drugs, vaccines, intravenous solutions, and implantable medical devices.

The importance of monocyte activation tests lies in their accuracy, human relevance, and ability to detect both endotoxins and non-endotoxin pyrogens. Unlike LAL tests, which only detect endotoxins, MAT can identify a broader spectrum of pyrogens, ensuring comprehensive safety assessments for pharmaceuticals and medical devices. MAT is aligned with the principles of the 3Rs (Replacement, Reduction, Refinement), which aim to minimize the use of animals in testing. This makes MAT not only effective in detecting pyrogens but also ethically aligned with modern regulatory requirements and industry standards in safety testing.

How Are Technological Advancements Shaping the Monocyte Activation Tests Market?

Technological advancements have significantly enhanced the efficiency, sensitivity, and reproducibility of Monocyte Activation Tests, driving innovation in pharmaceutical safety testing. One of the major developments is the use of cryopreserved human monocytes, which have improved the consistency and availability of MAT. Cryopreserved cells provide standardized and ready-to-use testing solutions, reducing variability in test results and improving reproducibility across different laboratories. This advancement has made MAT more accessible, especially in settings where fresh blood supply is limited or impractical.

The development of automated MAT platforms has further improved the scalability and efficiency of pyrogen testing. Automated systems streamline the entire testing process, from sample preparation to data analysis, reducing manual errors and enhancing throughput. Automation has made MAT more suitable for large-scale screening in biopharmaceutical manufacturing, where high-volume testing is required to ensure product safety. Additionally, the use of high-throughput screening (HTS) technologies has enabled faster identification of pyrogens, supporting rapid safety assessments during drug development and batch release.

Advancements in analytical techniques, such as multiplex cytokine assays and real-time PCR, have increased the sensitivity and accuracy of MAT. These techniques allow for the simultaneous measurement of multiple cytokines, providing a more comprehensive profile of pyrogenic activity. Integration with advanced data analytics and artificial intelligence (AI) tools has further improved the interpretation of MAT results, enabling faster and more precise decision-making in product safety evaluations. These technological innovations not only expand the capabilities of monocyte activation tests but also align with broader trends toward automation, higher sensitivity, and ethical testing in pharmaceutical safety.

What Are the Emerging Applications of Monocyte Activation Tests Across Different Sectors?

Monocyte Activation Tests are finding expanding applications across various sectors, driven by the need for reliable, ethical, and comprehensive pyrogen detection in biopharmaceuticals, medical devices, and vaccines. In the biopharmaceutical sector, MAT is widely used for testing injectable drugs, including biologics like monoclonal antibodies, recombinant proteins, and cell or gene therapies. The ability of MAT to detect both endotoxin and non-endotoxin pyrogens is critical for ensuring the safety of these complex biological products, where traditional LAL tests may miss certain contaminants.

In the vaccine industry, MAT plays a vital role in ensuring the safety of vaccines, particularly those developed through modern methods like mRNA or viral vectors. Given the need for rapid development and mass production, MAT offers a reliable, non-animal-based alternative that can be integrated into vaccine quality control pipelines. It is particularly valuable in detecting pyrogens in new vaccine formulations, such as those developed during the COVID-19 pandemic, where rapid, ethical, and accurate testing was essential.

In the medical device industry, MAT is used to test implantable devices, dialysis fluids, and intravenous solutions for pyrogenic contaminants. Since medical devices often come into direct contact with body fluids, rigorous pyrogen testing is necessary to prevent adverse immune reactions. MAT provides a more comprehensive safety assessment for these devices, supporting regulatory compliance and improving patient safety. In the cosmetic sector, MAT is used to evaluate the safety of injectable cosmetic products like dermal fillers, ensuring they are free from harmful pyrogens.

In research and development, MAT is increasingly employed during the early stages of drug and product development. Its use in preclinical testing allows researchers to identify and eliminate pyrogenic risks early in the development process, improving the likelihood of regulatory approval and reducing costs associated with late-stage failures. The expanding applications of MAT across these sectors highlight its critical role in enhancing safety, supporting ethical testing, and improving efficiency in the quality control of pharmaceuticals, medical devices, and related products.

What Drives Growth in the Monocyte Activation Tests Market?

The growth in the Monocyte Activation Tests (MAT) market is driven by several factors, including increasing demand for comprehensive pyrogen testing, rising adoption of ethical testing methods, and advancements in biopharmaceutical development. One of the primary growth drivers is the shift toward non-animal testing methods. As regulatory agencies like the FDA and EMA promote the adoption of in-vitro methods aligned with the 3Rs principles, MAT has gained traction as an effective alternative to animal-based pyrogen tests like the rabbit pyrogen test (RPT). This regulatory push toward ethical testing has accelerated the adoption of MAT in pharmaceutical and medical device manufacturing.

The growing complexity of biopharmaceuticals and advanced therapies has further fueled demand for MAT. With the rise of biologics, biosimilars, cell and gene therapies, and mRNA vaccines, there is a greater need for safety tests that can detect a wide range of pyrogens. MAT’s ability to identify both endotoxin and non-endotoxin pyrogens makes it a preferred choice for these advanced therapies, where traditional endotoxin tests may be insufficient.

Advancements in automation, high-throughput screening, and cryopreserved cell technology have also contributed to the growth of the MAT market. Automation and high-throughput capabilities have made MAT more scalable and efficient, supporting its use in large-scale biopharmaceutical production and batch release testing. The availability of cryopreserved monocytes has improved MAT’s reliability, reducing variability and making it more practical for routine use across different testing sites.

Stringent safety regulations and quality control standards in the pharmaceutical and medical device industries have further driven the adoption of MAT. Regulatory requirements for comprehensive pyrogen testing have made it essential for manufacturers to implement robust safety testing protocols. MAT not only meets these regulatory requirements but also offers a faster, more reliable, and ethical approach to pyrogen detection, making it a key component of modern safety assessment strategies.

With ongoing innovations in cell-based assays, regulatory support for in-vitro testing, and the growing complexity of biopharmaceutical products, the MAT market is poised for robust growth. These trends, combined with increasing demand for reliable, comprehensive, and ethical pyrogen detection, make MAT a vital component of pharmaceutical quality control, biopharmaceutical development, and regulatory compliance across various sectors.

SCOPE OF STUDY:

The report analyzes the Monocyte Activation Tests (MAT) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (MAT Kits, MAT Reagents); Source (Peripheral Blood Mononuclear Cell (PBMC) Based, Cell Line Based); End-Use (Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

• Becton, Dickinson & Company
• Charles River Laboratories International, Inc.
• Lonza Group AG
• Merck KgaA
• Microcoat Biotechnologie GmbH
• Sanquin
• Solvias AG
• Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Monocyte Activation Tests - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Need for Pyrogen Testing Drives Demand for Monocyte Activation Tests
  • Increasing Focus on Patient Safety in Drug Development Sets the Stage for Market Growth
  • Strong Regulatory Support for Safer Drug Testing Strengthens Business Case
  • Growing Use in Biopharmaceutical Production Expands Addressable Market
  • Growing Role in Quality Control Generates Demand in Pharmaceutical Industry
  • Increasing Focus on Animal-free Testing Drives Adoption of Monocyte Activation Tests
  • Expanding Use in Vaccine Safety Testing Sets the Stage for Market Expansion
  • Rising Focus on Endotoxin-free Manufacturing Generates Demand
  • Use in Cell Therapy Development Propels Monocyte Activation Test Market
  • Increasing Applications in Oncology and Immunotherapy Strengthen Market Position
  • Growing Role in Risk Assessment for Blood Products Drives Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Monocyte Activation Tests (MAT) Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for MAT Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for MAT Kits by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for MAT Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for MAT Reagents by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Peripheral Blood Mononuclear Cell (PBMC) Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Cell Line Based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Cell Line Based by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceutical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Pharmaceutical End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Biotechnology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Biotechnology End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Medical Device End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Medical Device End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 22: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 23: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 24: USA Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 28: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• JAPAN
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 34: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• CHINA
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 40: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 41: China 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 42: China Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• EUROPE
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 46: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• FRANCE
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 52: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 53: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 54: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 55: France 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• GERMANY
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 58: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 60: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• ITALY
  • TABLE 64: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 66: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• UNITED KINGDOM
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 70: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 71: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 72: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 73: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• ASIA-PACIFIC
  • Monocyte Activation Tests (MAT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Product Type - MAT Kits and MAT Reagents - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Product Type - Percentage Breakdown of Value Revenues for MAT Kits and MAT Reagents for the Years 2025 & 2030
  • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by Source - Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by Source - Percentage Breakdown of Value Revenues for Peripheral Blood Mononuclear Cell (PBMC) Based and Cell Line Based for the Years 2025 & 2030
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Monocyte Activation Tests (MAT) by End-Use - Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for Monocyte Activation Tests (MAT) by End-Use - Percentage Breakdown of Value Revenues for Pharmaceutical End-Use, Biotechnology End-Use, Medical Device End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION